Xromi (hydroxyurea) – New drug approval
April 4, 2024 - The FDA approved Rare Disease Therapeutics’ Xromi (hydroxyurea), to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age to less than 2 years, with sickle cell anemia with recurrent moderate to severe painful crises.